Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model

This study found that adipose-derived stem cells with DKK1 knocked out using CRISPR/Cas9 promoted hair growth in an alopecia areata model more effectively than untreated stem cells, suggesting DKK1 is a potential therapeutic target for this condition.

This systematic review and meta-analysis reports that patients with alopecia areata have significantly higher serum levels of IL6 and CRP, and lower levels of vitamin D, compared to healthy controls.

This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

This study suggests that hair follicle-derived mesenchymal stem cell transplantation may effectively treat acute pancreatitis by reducing inflammation and promoting pancreatic regeneration in a rat model.

Dermal exosomes with miR-218-5p boost hair growth by controlling β-catenin signaling.

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

This study proposes the miR-22-5p-LEF1 axis as a novel pathway that may regulate hair follicle stem cell proliferation.

This study suggests that mesenchymal stem cell therapy may improve cell viability and regulate key signaling pathways in vitro for treating alopecia areata.

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This review reports very low quality evidence for the effectiveness and safety of treatments in extensive resistant alopecia areata and emphasizes the need for high-quality randomized controlled trials.

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

This study found that the Stem Cell Educator therapy improved hair regrowth and quality of life in patients with severe alopecia areata by restoring immune balance and protecting hair follicles from autoimmune damage.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

This review discusses alopecia areata as a model for studying tissue-directed autoimmune diseases and reports no new clinical findings.